

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number
WO 2005/012572 A1

(51) International Patent Classification⁷: **C12Q 1/68**

(21) International Application Number:
PCT/KR2004/001903

(22) International Filing Date: 28 July 2004 (28.07.2004)

(25) Filing Language: Korean

(26) Publication Language: English

(30) Priority Data:
10-2003-0053534 1 August 2003 (01.08.2003) KR

(71) Applicants (for all designated States except US): **CJ CORP.** [KR/KR]; 500 Namdaemunno 5-ga, Jung-gu, Seoul 100-802 (KR). **PROTHEON CO., LTD.** [KR/KR]; 134 Sinchon-dong, Seodaemun-gu, Seoul 120-140 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LEE, Jang Yun** [KR/KR]; #2-202, Suji CJ Villa, 19-1, Pungdeokcheon 1-dong, Yongin-si, Gyeonggi-do 449-551 (KR). **KIM, Jae Seung** [KR/KR]; #101-303, Poongsan 1-cha Apt., Songjeong-dong, Icheon-si, Gyeonggi-do 467-711 (KR).


KIM, Hyun Ah [KR/KR]; #201 660-4, Pungdeokcheon 1-dong, Yongin-si, Gyeonggi-do 449-552 (KR). **KIM, Yeon Hee** [KR/KR]; #301, Colorhouse, 868-27, Bangbae 4-dong, Seocho-gu, Seoul 137-838 (KR). **HA, Suk Hoon** [KR/KR]; #102-104, Sambu Apt., Samseong-dong, Gangnam-gu, Seoul 135-090 (KR). **LEE, Nam Joong** [KR/KR]; #128-104, Hyundai Fally Apt., Gaebong-dong, Guro-gu, Seoul 152-090 (KR). **PARK, Wan Je** [KR/KR]; #105-808, Hanguk 1-cha Apt., 1211, Mactan 2-dong, Yeongtong-gu, Suwon-si, Gyeonggi-do 443-712 (KR). **MOON, Moo Sang** [KR/KR]; #10-907, Plaza Apt., 199, Garak 2-dong, Songpa-gu, Seoul 138-746 (KR). **SEONG, Baik Lin** [KR/KR]; #21-302, Hyundai Mansion, Sinsa-dong, Gangnam-gu, Seoul 135-120 (KR). **LEE, Kwang Hee** [KR/KR]; 13-48 Changcheon-dong, Seodaemun-gu, Seoul 120-833 (KR).

(74) Agent: **SON, Min**; 19th Floor, City Air Tower, 159-9 Samsung-dong, Kangnam-gu, Seoul 135-973 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH,

[Continued on next page]

(54) Title: SCREENING METHOD OF REASSORTANT INFLUENZA VIRUSES USING PRIMER DEPENDENT MULTIPLEX RT-PCR



(57) Abstract: Disclosed is a screening method of genes of reassortant influenza viruses in a reassortant influenza virus preparation process by using a difference between primers in binding specificity to templates in multiplex RT-PCR. The screening method is characterized by simultaneously performing two or three PCRs in a single tube using primers that are designed to correspond to poorly conserved regions selected by a homology search between nucleotide sequences of genes of an attenuated influenza virus and those of a virulent virus, thereby effectively screening a 6:2 reassortant virus containing six internal genes from an attenuated influenza virus and two external genes from a virulent virus.



PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

SCREENING METHOD OF REASSORTANT INFLUENZA VIRUSES
USING PRIMER DEPENDENT MULTIPLEX RT-PCR

Technical Field

The present invention relates to a screening method
5 of genes of reassortant influenza viruses in a reassortant
influenza virus preparation process by using a difference
between primers in binding specificity to templates in
multiplex RT-PCR.

Background Art

10 Influenza is an acute respiratory illness caused by
infection of influenza viruses, which exhibits upper and
lower respiratory symptoms as well as fever, headache,
muscle aches and asthenia. Influenza infection occurs
almost every winter with various symptoms and pathogenic
15 states according to pandemic subtypes of influenza viruses.
Since influenza infection is highly epidemic and often
causes pneumonia and complications associated with heart
and lung diseases with high mortality, the elderly, young
children and even adults are recommended to be vaccinated
20 with influenza vaccines.

Influenza viruses belong to the family
Orthomyxoviridae and contain eight negative-sense RNA
segments encoding PB2, PB1, PA, HA, NP, NA, M and NS. Among

the proteins, two outer envelope proteins, hemagglutinin (hereinafter, referred to as simply "HA") and neuraminidase (hereinafter, referred to as simply "NA") are potent immunogens that induce production of antibodies against influenza viruses, and are modified by the antigenic shift and drift processes. The high variability of HA and NA allows an influenza virus to escape the immunity formed against other influenza viruses within an identical subtype. Since immune responses induced by an influenza virus typically disappear in a short time, immunization against viruses predicted to spread should be newly performed every season.

In the case of influenza vaccines, inactivated vaccines against some influenza virus strains (two strains for type A and one strain for type B), epidemics of which have been expected by the World Health Organization (WHO), are typically used. Three inactivated influenza vaccines are widely used: whole virus vaccines using whole inactivated virions of influenza viruses; influenza split vaccines prepared by disrupting and inactivating influenza virus particles while maintaining their antigenicity; and influenza HA vaccines prepared by using only hemagglutinin isolated from influenza viruses. Viruses used in preparing these inactivated vaccines are typically cultured in fertilized eggs, and recently, their production by cell culturing has been attempted.

However, influenza viruses epidemics which have been

predicted by WHO have low proliferation capacity in fertilized eggs, resulting in low productivity. Productivity can be improved by reassorting a target strain with a virus strain adapted for high growth in fertilized
5 eggs, thus generating a 6:2 reassortant virus containing genome segments encoding the viral surface antigens, HA and NA, which are derived from the target strain, and the remaining six internal genome segments from the high-yielding strain. This method has been applied to improve
10 vaccine productivity in fertilized eggs for a long time (Influenza, Plenum Medical Book Company, 291, 1987).

Inactivated vaccines provide protective efficacy rates greater than 70% in young adults and are effective in reducing hospitalization due to respiratory illnesses and
15 secondary infections such as pneumonia. However, they have disadvantages of having short immunity duration and being intramuscularly administered and not inducing production of mucosal secretory antibodies (sIgA) responsible for initial protection against viral infections. The disadvantages
20 further include that the inactivated vaccines do not induce the CTL immunity sufficiently leading to death of infected cells.

Many efforts were made to develop live influenza vaccines that overcome the disadvantages of the inactivated
25 vaccines, are highly immunogenic and are administered intranasally through the nasal mucosa. The first effort was made in the Soviet Union in 1965, resulting in the

development of a live vaccine virus strain using a cold-adapted attenuated virus strain, and, at present, still many studies associated with live influenza vaccines have been performed (Rev Roum Infra microbiol 2, 179-89, 1965). In the
5 Soviet Union, a reassortant virus was developed by using an A/Leningrad/134/47/57(H2N2) virus as a donor virus strain for a live vaccine. In America, clinical trials for a live vaccine containing a reassortant virus strain that had been prepared by employing an A/Ann Arbor/6/60(H2N2) virus as a
10 donor virus strain were completed, and the live vaccine was licensed for vaccination for people between the ages of 5 and 49.

To accomplish high productivity and safety of inactivated vaccines and live vaccines, a reassortant virus
15 should be prepared by reassorting a target virus with a strain having high productivity in fertilized eggs or an attenuated virus strain. Since combinations occur randomly between eight RNA segments of influenza viruses during reassortant virus preparation, a maximum of 2^8 , that is,
20 256, different reassortant viruses can be produced. Thus, it is very important to establish a rapid and efficient selection method of 6:2 reassortant, that possesses the attenuation property of the donor virus and contains the outer proteins of virulent viruses, HA and NA virus, from
25 the produced reassortant viruses:

A 6:2 reassortant virus is prepared as follows. First, a virulent virus is mixed with a donor virus in a

predetermined ratio, and the mixed viruses are inoculated in 11-day-old fertilized eggs. The eggs are incubated at a low temperature to produce reassortant viruses by random combinations. To select only viruses having the cold adaptation property of the donor virus and containing outer envelope proteins from the virulent virus, sub-culturing in fertilized eggs is performed at a low temperature in the presence of an antibody specific to the donor virus. A single virus clone is obtained by plaque isolation in the presence of an antibody specific to the donor virus, and is grown again in fertilized eggs to be propagated. HA and NA on the multiplied virus can be rapidly analyzed by a hemagglutinin inhibition assay (hereinafter, referred to simply as "HI") and a neuraminidase inhibition assay (hereinafter, referred to simply as "NI"). However, the remaining six internal genes are genetically analyzed.

For analysis of genes of reassortant influenza viruses, RNA genome can be directly analyzed by a method based on analyzing a difference of single-stranded RNA molecules in migration on a PAGE (polyacrylamide gel electrophoreses) gel, which is caused by different RNA sequences (J. Virol. 29,1142-1148,1979), Northern blotting and Crot analysis (RNA-DNA hybridization) (J. Gen. Virol. 64, 2611-2620, 1983; Vaccine 3, 267-273, 1985). However, these methods are problematic in terms of direct use of easily degradable RNA molecules. Also, they are cumbersome because RNA should be run on a PAGE gel for a long time.

Further, since the methods analyze a difference in nucleotide sequences of genes based on the difference in migration on a gel, they often lead to inaccurate results.

To solve these problems, a RFLP (Restriction Fragment Length Polymorphism) method was introduced, which analyses the gene by a combination of Reverse Transcription-Polymerase Chain Reaction (hereinafter, referred to simply as "RT-PCR") and the specificity of restriction enzymes (J. Virol. Methods 52, 41-49, 1995). RFLP is the most commonly used method for comparing patterns obtained by digesting genomes of donor and virulent viruses with restriction enzymes. However, there are drawbacks with the RFLP method, as follows. Eight RNA genome segments of influenza viruses should be individually isolated and amplified by RT-PCR and then digested with restriction enzymes. The nucleotide sequence of a virulent virus should first be analyzed to select proper restriction enzymes. Also, it takes many times to find proper restriction enzymes capable of distinguishing a donor virus and a virulent virus. Further, when variations occur in specific nucleotide sequences recognized by selected restriction enzymes, inaccurate results are obtained.

In addition to the above application, RT-PCR has been used for detecting influenza viruses and identifying subtypes thereof. However, when used for screen reassortant viruses, the RT-PCR method has a limitation in rapidly, effectively distinguishing genes from a donor virus and a virulent virus.

In this regard, the present inventors developed a method of rapidly distinguishing only a reassortant virus capable of being used as a live vaccine from various combinations of a virus by designing a plurality of primers specific to a donor virus and improving a PCR method, and completed the present invention by practically applying the method for screening reassortant viruses with two to four genes amplified in an identical reaction and confirming its effectiveness.

10 Disclosure of the Invention

In an aspect, the present invention provides oligonucleotide primers allowing rapid screening of reassortants of a cold-adapted influenza virus, HTCA-A101 (Accession No.: KCTC 0400 BP), and a type A influenza virus.

In another aspect, the present invention provides a screening method of reassortant viruses by a multiplex RT-PCR method using pairs of the oligonucleotide primers.

Brief Description of the Drawings

20 The above and other objects, features and other advantages of the present invention will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which:

Fig. 1 shows the results of RT-PCR performed using PB2 primer sets listed in Table 1 to amplify PB2 of eight RNA segments of an attenuated virus strain HTCA-A101 (M: molecular marker; lanes 1 to 9: PB2 primer sets 1 to 9 according to the present invention; and C: positive PB2 primer set);

Fig. 2 shows the results of RT-PCR performed using PB2 primer sets listed in Table 1 to amplify PB2 of eight RNA segments of each of four virulent viruses, A/New Caledonia/20/99 (H1N1), A/Moscow/10/99 (H3N2), A/Beijing/262/95 (H1N1) and A/Shangdong/9/93 (H3N2), wherein the numbers and capitals in an upper part are the same as those in Fig. 1;

Fig. 3 shows the results of multiplex PCR performed concurrently under identical conditions using as a template cDNA of each two virulent viruses, A/New Caledonia/20/99 (H1N1) and A/Moscow/10/99 (H3N2), wherein, the A of Fig. 3 shows the results for a virulent virus, A/New Caledonia/20/99 (H1N1) [M: molecular marker; lanes 1 to 3 shows the results for eight RNA segments of the attenuated virus strain, which are obtained using specific primer sets, lane 1: PB2, PB1 and NP; lane 2: M, NS and PA; and lane 3: HA and NA, in detail, lane 1: PB2-2 (1002 bp), NP-4 (853 bp) and PB1-6 (559 bp); lane 2: PA-5 (730 bp), NS-5 (521 bp) and M-6 (326 bp); and lane 3: HA-4 (1086 bp) and NA-4 (504 bp); lanes 4 to 6 show the results obtained using the same primer sets as in lanes 1 to 3; lanes 7 to 14 show the results of positive controls for

eight RNA segments, wherein lanes 13 and 14 show the results obtained using specific primer sets for H1 and N1 subtypes of A/New Caledonia/20/99 (H1N1)], and the B of Fig. 3 shows the results for another virulent virus, A/Moscow/10/99 (H3N2) [M: molecular marker; lanes 1 to 3 show the results for eight RNA segments of the attenuated virus strain, which are obtained using specific primer sets, lane 1: PB2, PB1 and NP; lane 2: M, NS and PA; and lane 3: HA and NA, in detail, lane 1: PB2-2 (1002 bp), NP-4 (853 bp) and PB1-6 (559 bp); lane 2: PA-5 (730 bp), NS-5 (521 bp) and M-6 (326 bp); and lane 3: HA-4 (1086 bp) and NA-4 (504 bp); lanes 4 to 6 show the results obtained using the same primer sets as in lanes 1 to 3; lanes 7 to 14 show the results of positive controls for eight RNA segments, wherein lanes 13 and 14 show the results obtained using specific primer sets for H3 and N2 subtypes of A/Moscow/10/99 (H3N2)];

Fig. 4 shows analysis results using a screening method according to the present invention for viruses obtained by infecting a single fertilized egg with a virulent virus A/New Caledonia/20/99 (H1N1) and an attenuated virus strain, growing the viruses in the egg, reacting obtained viruses with an antibody against the attenuated virus strain and isolating plaques, wherein four lanes show the results for a single virus (lanes 1 to 3: the results of multiplex PCR to investigate the origin of eight genes; lane 4: the results of PCR for M (649 bp) of eight genes as a positive control to monitor the presence or

absence of genes during RNA preparation and RT-PCR), which are obtained using primer sets, lane 1: PB2-2 (1002 bp), NP-4 (853 bp) and PB1-6 (559 bp); lane 2: PA-5 (730 bp), NS-5 (521 bp) and M-6 (326 bp); lane 3: HA-4 (1086 bp), and NA-4 (504 bp); and lane 4: Positive M (649 bp).

Best Mode for Carrying Out the Invention

To prepare a reassortant virus possessing the attenuation property of a donor virus and containing outer envelope proteins from a virulent virus, it is most important to select a virus strain including internal genes from the donor virus and outer envelope protein genes from the virulent virus by analyzing genes of obtained reassortant viruses to identify the origin of the genes.

However, primer design for determining whether genes are derived from the donor virus or the virulent virus requires a long time. Also, RNA isolation from a plurality of reassortant viruses obtained by various combinations and analysis of the isolated RNA require a lot of effort and time. With regard to the situation that live vaccine virus strains should be prepared using viruses recommended by WHO and produced for a short period of time (about one to two months) in the Northern Hemisphere, related studies should be focused on such work and to develop methods allowing vaccine production in a short period of time.

In this regard, the present inventors designed a

plurality of primers specific to an attenuated donor virus by analyzing the influenza virus database accumulated so far, and selected primers allowing a distinction between a donor virus and a virulent virus by RT-PCR for the two
5 viruses in a matrix form. Introduction of a multiplex PCR method using the selected primers resulted in the development of a method capable of rapidly identifying a virus of interest by only three or four reactions.

Therefore, in an aspect, the present invention aims
10 to provide primer sets specifically reacting with a donor virus HTCA-A101 and a PCR method using the primer sets for screening 6:2 reassortants of a donor virus and a type A influenza virus.

In another aspect, the present invention aims to
15 provide a multiplex PCR method which is simpler and more economical than the case of simultaneously performing multiple PCRs.

In addition, the use of the multiplex PCR method according to the present invention may lead to rapid
20 screening for 6:2 reassortant viruses.

In more detail, the present invention provides a PCR method for screening a 6:2 reassortant of a donor virus and a virulent virus, comprising the steps of designing PCR primer sets producing PCR products from a genome of an
25 attenuated donor virus while not producing PCR products from a genome of a virulent virus on amplification for eight RNA genome segments of influenza viruses; infecting a

fertilized egg with the virulent virus and the attenuated donor virus and allowing random reassortment between the two viruses to produce reassortant viruses; preparing cDNA by reverse transcription of an RNA genome of each of the
5 reassortant viruses; performing PCR for the eight RNA genome segments using the reassortant virus cDNA and a primer set for each of the eight RNA genome segments, wherein the primer set allows PCR products to have different lengths; and selecting a reassortant virus with
10 which six internal RNA genome segments (PB2, PB1, PA, NP, M and NS) are amplified while two RNA genome segments encoding outer envelope proteins (HA and NA) are not amplified in a PCR using primer sets specific to the attenuated donor virus.

15 More preferably, the present invention provides a PCR method using an HTCA-A101 strain (KCTC 0400 BP) as an attenuated donor virus.

In addition, in the present invention, type A influenza viruses, A/Moscow/10/99, A/New Caledonia/20/99,
20 A/Shangdong/9/93 and A/Shangdong/6/86, are used as target virulent viruses for screening for illustrative purpose, but the present invention is not limited to these viruses.

The present invention also provides a multiplex PCR method in which amplification for the eight genes is
25 performed in three or four tubes while two or three PCRs occur simultaneously in a single tube.

In more detail, the present invention provides a

multiplex PCR method in which primer sets for PB2, PB1 and NP; M, NS and PA; and HA and NA are put into, respectively, a first tube, a second tube and a third tube, and, when PCRs are carried out for a reassortant virus in the tubes, PCR products are produced only in the first and second tubes. Herein, since HA and NA are major immunogenic proteins, when the reassortant virus is to be used as an inactivated or live vaccine, the two proteins should be derived from the virulent virus.

Therefore, preferably, the present invention provides a multiplex PCR method of screening a 6:2 reassortant of a donor virus and a virulent virus.

The PCR and RT-PCR according to the present invention may be carried out by a PCR method generally known in the art, preferably by one cycle of denaturation at 94°C for 5 min, and 30 cycles of denaturation at 94°C for 30 sec, annealing at 55°C for 1 min and elongation at 72°C for 1 min 20 sec, but the present invention is not limited to these PCR conditions.

The present invention also provides primer sets listed in Table 1 for use in the PCR method, which are specific for eight RNA genome segments including six internal genes and two outer envelope proteins of the attenuated donor virus.

An influenza virus as mentioned in the present invention contains six non-immunogenic genes, PB2, PB1, PA, NP, M and NS, and two immunogenic genes, HA and NA. The PCR

method according to the present invention allows rapid screening for a 6:2 reassortant virus for use as an inactivated or live vaccine by employing specific primer sets producing PCR products specific for an attenuated
5 donor virus HTCA-A101 while not producing PCR products specific for a virulent virus.

Hereinafter, the present invention will be described in more detail.

1. Oligonucleotide primer design

10 A homology search was first performed between the donor virus and virulent viruses using influenza virus sequence database, and primers were designed in regions with low homology. Primers were designed to have a length of about 19-21 bases. At least 2 or 3 bases at a 3'-end of
15 each of the primers corresponded to a region having different bases in a continuous sequence of the donor virus and the virulent virus. Also, the primers were designed to have an annealing temperature of about 58-60°C for optimal multiplex PCR performance. In target sequences, regions
20 having variations were preferentially selected, and regions having a run of an identical base were excluded to provide donor virus-specific primers. The resulting primers that have a sequence corresponding to the regions of low homology were used for screening according to the present
25 invention. Regions of high homology (100% homology based on the database) in the target sequences were used for the

design of positive control primers that were used in RT-PCR. In detail, in the present invention, a cold-adapted A/X-31 virus strain, HTCA-A101 (hereinafter, referred to simply as "A101") was used as a donor virus. Nucleotide sequences of type A influenza viruses for homology search with the donor virus were obtained from an influenza virus database at a web site (<http://www.flu.lanl.gov>), and a homology search was carried out using nucleotide sequences of H3N2 and H1N1 subtypes infecting humans. A homology search was carried out not by a 1:1 alignment between A101 and a virulent virus but by a multiple alignment between A101 and viruses registered in the database, particularly, all human-infecting viruses having a complete sequence registered in the database. Consistent criteria were difficult to apply for all target sequences on selection of specific regions for primer design because genome segments have different sequence homology levels. To easily detect PCR products according to their size, regions providing the largest difference in size of PCR products were selected in the target sequences.

2. RT-PCR analysis of templates from A101 and the virulent virus

First, optimal conditions for amplification of all eight RNA genome segments of A101 were established using the primer sets as prepared above. PCR products obtained from a genome from A101 were compared with those obtained

from a genome from the virulent virus under the same conditions.

3. Establishment of optimal conditions for multiplex RT-PCR

After primers producing PCR products from a genome of the donor virus strain while not producing PCR products from a genome of the virulent virus were selected, a set of the selected primers was selected for each of the eight genes to be amplified, and eight PCRs were designed to be carried out in three tubes.

Conventional techniques associated with multiplex RT-PCR conditions are concentrated on the reduction of interactions of primers with PCR products to produce multiple PCR products in a single template. In contrast, the present invention is characterized in that different PCRs for the eight genes happen simultaneously on eight templates from the virulent virus. In addition, to distinguish PCR products from each other on an agarose gel, combinations of primers were determined with regard to the size of PCR products. This multiplex RT-PCR allows the identification of the origin of genes of a reassortant virus, and its results were correlated with results of partial nucleotide sequence analysis.

A better understanding of the present invention may be obtained through the following examples which are set forth to illustrate, but are not to be construed as the limit of the present invention.

EXAMPLE 1: Design and synthesis of oligonucleotide primers

Influenza A viruses contain eight negative-sense RNA segments encoding PB2, PB1, PA, HA, NP, NA, M and NS. The eight genes were subjected to a homology search between human-infecting H3N2 and H1N1 subtypes and an attenuated virus, HTCA-A101, using nucleotide sequences obtained from an influenza virus database at a web site (<http://www.flu.lanl.gov>). Multiple alignment was carried out with a VECTOR NTI's alignment program. Six regions of low homology were selected for each gene: three for 5' primers (sense primers) and three for 3' primers (antisense primers). By various combinations of the primers, nine primer sets were designed for each of PB2, PB1, PA, NP, M and NS genes. For HA and NA genes, four regions were selected for each gene: two for 5' primers and two for 3' primers. Using these primer sets, PCR products specific for a template from the HTCA-A101 virus were produced. In contrast, positive control primers were designed to correspond to regions of high homology. One positive control primer was designed for each of PB2, PB1, PA, NP, M and NS, and two positive control primers were designed for each of HA and NA genes. Nucleotide sequences of the primers and size of PCR products are given in Tables 1a to 1d, below.

Nucleotide sequences of the primers and size of amplified products

TABLE 1a

Target gene	Primer set No.	Position	Length (bp)	Sense primer (5'→3')	Antisense primer (5'→3')
PB2	PB2-1	337-1885	1549	5'-1 AATGACAATAACAGTTAC	3'-1 GAGCAGTTTATTA TCTGTGC
	PB2-2	834-1885	1052	5'-2 CACACAGATTGGTGAATT	3'-1 GAGCAGTTTATTA TCTGTGC
	PB2-3	1423-1885	464	5'-3 CGACATGACTCCAG CATT	3'-1 GAAGAAGTTTATTA TCTGTGC
	PB2-4	337-2116	1780	5'-1 AATGACAATAACAGTTAC	3'-2 GAATGAGGANTCCCC TCAGA
	PB2-5	834-2116	1283	5'-2 CACACAGATTGGTGAATT	3'-2 GAATGAGGANTCCCC TCAGA
	PB2-6	1423-2116	695	5'-3 CGACATGACTCCAG CATT	3'-2 GAATGAGGANTCCCC TCAGA
*	PB2-7	337-2135	1799	5'-1 AATGACAATAACAGTTAC	3'-3 CTCCTGCTCTCTTTG CCCAG
	PB2-8	834-2135	1292	5'-2 CACACAGATTGGTGAATT	3'-3 CTCCTGCTCTCTTTG CCCAG
	PB2-9	1423-2135	714	5'-3 CGACATGACTCCAG CATT	3'-3 CTCCTGCTCTCTTTG CCCAG
	Positive PB2	1622-2270	649	5' CATCGTCAATGATCTGGAG	3' TGCCCTGTCAGTAAGT ATGCT
	PB1-1	1026-1432	407	5'-1 AAATGT TCTAAGTATTGC TCCA	3'-1 AGGTTGCGATATAAACCCTGCG
	PB1-2	1026-1432	237	5'-2 GAGACGACAGATATGAACCTTA	3'-1 AGGTTGCGATATAAACCCTGCG
	PB1-3	1141-1432	292	5'-3 CTAGGACGATCGATTTCAAA	3'-1 AGGTTGCGATATAAACCCTGCG
	PB1-4	1026-1719	694	5'-1 AAATGTTCTAAGTATTGCTCCA	3'-2 GTCACCTCTATGGCATCCG
	PB1-5	1026-1719	624	5'-2 GAGACGACAGATATGAACCTTA	3'-2 GTCACCTCTATGGCATCCG
	PB1-6	1141-1719	579	5'-3 CTAGGACGATCGATTTCAAA	3'-2 GTCACCTCTATGGCATCCG
	PB1-7	1026-1962	937	5'-1 AAATGTTCTAAGTATTGCTCCA	3'-3 CATCATCACTGCGATTGTCATT
	PB1-8	1026-1962	957	5'-2 GAGACGACAGATATGAACCTTA	3'-3 CATCATCACTGCGATTGTCATT
	PB1-9	1141-1962	822	5'-3 CTAGGACGATCGATTTCAAA	3'-3 CATCATCACTGCGATTGTCATT
	Positive PB1	1243-2268	1026	5' ATGATGATGGCATGTTTCAA	3' GAACAGATCTTCATGATCT

TABLE 1b

Target gene	Primer set No.	Position	Length (bp)	Sense primer (5'→3')	Antisense primer (5'→3')
PA	PA-1	257-1336	1080	5'-1 TAAATCAGGGGAGAGATGCG	3'-1 TGTGTTCAATTGGAGCACA
	PA-2	811-1336	526	5'-2 ACAACACCAACCACTTAG	3'-1 TGTGTTCAATTGGAGCACA
	PA-3	971-1336	366	5'-3 GATGGAGGAGACCCCAATGTT	3'-1 TGTGTTCAATTGGAGCACA
	PA-4	257-1541	1285	5'-1 TAATCCAGGAGAGATCCG	3'-2 TTTATGATGAACCAACAAGC
	PA-5	811-1541	731	5'-2 ACAACACCAACCCACCTTAG	3'-2 TTTATGATGAACCAACAAGC
	PA-6	971-1541	571	5'-3 GATGGAGGAGACCCCAATGTT	3'-2 TTTATGATGAACCAACAAGC
	PA-7	257-1710	1451	5'-1 TAATCAGGGGAGAGATCCG	3'-3 GAACATGGGCCCTTGAACCT
	PA-8	811-1710	900	5'-2 ACAACACCAACCACTTAG	3'-3 GAACATGGGCCCTTGAACCT
	PA-9	971-1710	740	5'-3 GATGGAGGAGACCCCAATGTT	3'-3 GAACATGGGCCCTTGAACCT
NP	Positive PA	34-586	533	5' GTAGTCTGGCTTTTGTGGCC	3' TCTTGCTTTATGGTCAATAG
	NP-1	327-1120	794	5'-1 ACCTATATACAGGAGTAAC	3'-1 AAAGCTTCCCTCTTGGGAGC
	NP-2	805-1120	516	5'-2 GAACAATGGTGATGGAATTGG	3'-1 AAAGCTTCCCTCTTGGGAGC
	NP-3	905-1120	216	5'-3 GTGGGTACGACTTTGAACGG	3'-1 AAAGCTTCCCTCTTGGGAGC
	NP-4	327-1181	855	5'-1 ACCTATATACAGGAGTAAC	3'-2 AGTGTACTTGTATCCATAGTC
	NP-5	805-1181	577	5'-2 GAACAATGGTGATGGAATTGG	3'-2 AGTGTACTTGTATCCATAGTC
	NP-6	905-1181	277	5'-3 GTGGGTACGACTTTGAACGG	3'-2 AGTGTACTTGTATCCATAGTC
	NP-7	327-1329	1003	5'-1 ACCTATATACAGGAGTAAC	3'-3 TCGTGCATATATGTTGGTTC
	NP-8	805-1329	725	5'-2 GAACAATGGTGATGGAATTGG	3'-3 TCGTGCATATATGTTGGTTC
	NP-9	905-1329	425	5'-3 GTGGGTACGACTTTGAACGG	3'-3 TCGTGCATATATGTTGGTTC
	Positive NP	392-1505	1114	5' TAAGGCGAATCTGGGCCAA	3' TAAGATCCTTTCATTACTCAT

TABLE 1c

Target gene	Primer set no.	Position	Length (bp)	Sense primer (5'→3')	Antisense primer (5'→3')
M	M-1	55-655	502	5'-1 AGTACTCTCTATCATGCG	3'-1 TCTAGCCTGACTAGCAACC
	M-2	353-655	304	5'-2 CCATGGGGCCAAAGAATCT	3'-1 TCTAGCCTGACTAGCAACC
	M-3	485-655	171	5'-3 ATTGCTGACTCCGAGCATC	3'-1 TCTAGCCTGACTAGCAACC
	M-4	55-811	757	5'-1 AGCTACTCTCTATCATGCG	3'-2 TGAATTTGGGGCAATAGTG
	M-5	353-811	459	5'-2 CCATGGGGCCAAAGAATCT	3'-2 TGAATTTGGGGCAATAGTG
	M-6	485-811	326	5'-3 ATTGCTGACTCCGAGCATC	3'-2 TGAATTTGGGGCAATAGTG
	M-7	55-937	883	5'-1 AGCTACTCTCTATCATGCG	3'-3 CTTCCTCATAGACTTTGGC
	M-8	353-937	585	5'-2 CCATGGGGCCAAAGAATCT	3'-3 CTTCCTCATAGACTTTGGC
	M-9	485-937	452	5'-3 ATTGCTGACTCCGAGCATC	3'-3 CTTCCTCATAGACTTTGGC
NS	Positive M	248-914	667	5'- GGAGCGTAGACGCTTTGTC	3'- CCTTCGGTAGAAGGCCCTC
	NS-1	89-465	377	5'-1 AGTTGCAGACCAAGCACTAG	3'-1 GCAATATAGAGTCTCCAGC
	NS-2	185-465	280	5'-2 ATCAAGACAGCCACACGTGC	3'-1 GCAATATAGAGTCTCCAGC
	NS-3	207-465	259	5'-3 GGAAGCAGATAGTGGAGCG	3'-1 GCAATATAGAGTCTCCAGC
	NS-4	89-705	618	5'-1 AGTTGCAGACCAAGCACTAG	3'-2 CTAATTGTTCCCGCCATTCT
	NS-5	185-705	521	5'-2 ATCAAGACAGCCACACGTGC	3'-2 CTAATTGTTCCCGCCATTCT
	NS-6	207-705	500	5'-3 GGAAGCAGATAGTGGAGCG	3'-2 CTAATTGTTCCCGCCATTCT
	NS-7	89-774	686	5'-1 AGTTGCAGACCAAGCACTAG	3'-3 ATTCTCTGTTATCTTCAGTT
	NS-8	185-774	589	5'-2 ATCAAGACAGCCACACGTGC	3'-3 ATTCTCTGTTATCTTCAGTT
	NS-9	207-774	588	5'-3 GGAAGCAGATAGTGGAGCG	3'-3 ATTCTCTGTTATCTTCAGTT
	Positive NS	1-812	612	5'- AGCAAAAGCAGGGTGACAAA	3'- CAGAGACTCGAAGCTGTGTTA

TABLE 1d

Target gene	Primer set No.	Position	Length (bp)	Sense primer (5'→3')	Antisense primer (5'→3')
HA	HA-1	447-1277	831	5'-1 GGTTCACCTGGACTGGGGT	3'-1 TGAGAAATTCCTTTTCGATTGA
	HA-2	447-1623	1177	5'-2 TGACCAAAATCAGGAAGCA	3'-1 TGAGAAATTCCTTTTCGATTGA
	HA-3	538-1277	740	5'-1 GGTTCACCTGGACTGGGGT	3'-2 GCATCCAGTCTTTGTATCCA
	HA-4	538-1623	1086	5'-2 TGACCAAAATCAGGAAGCA	3'-2 GCATCCAGTCTTTGTATCCA
NA	Positive H1 Control	33-629	597	H1-5' ATGAAAGCCMAAAGCTACTAGTTCA	H1-3' AGACGGGTGATGAAACACCCCAT
	Positive H3 Control	214-839	626	H3-5' CCTCAACAGGTAGATATATGCGG	H3-3' AGGAGCAATTTAGATTCCCTGTG
	NA-1	227-1002	776	5'-1 AGATATGCCGCCAAATTAG-G	3'-1 CGATTGTTAGCCAGCCCATGCCA
	NA-2	227-1171	945	5'-2 TGGGTTTGTATCAATGGGAC	3'-1 CGATTGTTAGCCAGCCCATGCCA
	NA-3	668-1002	335	5'-1 AGATATGCCGCCAAATTAGTG	3'-2 CTGGATTTGGAAATAGGTG
	NA-4	668-1171	504	5'-2 TGGGTTTGTATCAATGGGAC	3'-2 CTGGATTTGGAAATAGGTG
	Positive N1 Control	1-600	600	N1-5' AGCAAAAGCAGGAGTTTAAAA	N1-3' CGATTGTTAGCCAGCCCATGCCA
	Positive N2 Control	20-402	383	N2-5' ATGAATCCAAATCAAAAGATAA	N2-3' TTGCCAGGATGCCATGACACAT
Ctrl 12	1-AGCAAAAGCAGG-12				

EXAMPLE 2: RNA genome isolation from influenza viruses

RNA was isolated using a TRIZOL LS reagent (GibcoBRL Company) directly from viral culture fluids. 900 μ l of the
5 TRIZOL LS reagent was added to 300 μ l of a viral culture fluid, and 200 μ l of chloroform was added thereto. After being vigorously mixed for 10 sec, the fluid was centrifuged at 12,000 rpm for 10 min. The supernatant was transferred to a new tube and supplemented with an equal
10 volume of isopropanol. After being allowed to stand at room temperature for 10 min, the tube was centrifuged at 12,000 rpm for 5 min. After the supernatant was discarded, 1 ml of 75% ethanol was added to the tube. After vortexing, the tube was centrifuged at 12,000 rpm for 10 min to
15 precipitate RNA. The resulting RNA pellet was dissolved in RNase-free water, aliquotted and stored at -70°C until use.

In addition to the donor virus strain, influenza viruses used in this RNA isolation included four influenza A viruses recently causing epidemics, A/New Caledonia/20/99 (H1N1), A/Moscow/10/99 (H3N2), A/Singapore/6/86 (H1N1) and
20 A/Shangdong/9/93 (H3N2).

EXAMPLE 3: Preparation of cDNA from influenza RNA genome viruses

After concentration of the isolated RNA was

determined by measuring absorbance at 260 nm, reverse transcription was carried out using a total of 2 µg of RNA as a template and a QIAGEN's Omniscript RT kit. A reaction mixture was prepared by mixing 12 µl of a RNA solution, 2
5 µl of 5 mM dNTP, 2 µl of 10× RT buffer, 2 µl of 10 pmol/ul primer (a conserved sequence in 3' end of all eight negative-sense RNA segments of influenza viruses: 5'-AGCGAAAGCAGG-3') and 1 µl of reverse transcriptase. The reaction mixture was incubated at 37° for 60 min to induce
10 cDNA synthesis, and then was incubated at 94° for 5 min to inactivate reverse transcriptase. The synthesized cDNA was used in all PCRs for the eight genes.

EXAMPLE 4: Detection of PCR products for the donor virus and the virulent virus

15 PCR was carried out to determine whether PCR products are produced from templates from the virulent virus and the donor virus by the specificity of the primers. PCR was carried out using 1 µl of the cDNA solution prepared in Example 3 and a primer set for each gene prepared in
20 Example 1. PCR conditions included denaturation at 94°C for 5 min, and 30 cycles of denaturation at 94°C for 30 sec, annealing at 55°C for 1 min and elongation at 72°C for 1 min 20 sec.

The amplified PCR products were separated on an
25 agarose gel. As a result, in the case of the donor virus,

PCR products were produced from all combinations of primers corresponding to regions of low homology, that is, nine primer sets for each of the six internal genes and four primer sets for each of the two external genes encoding outer envelope proteins HA and NA. In contrast, in the case of the virulent viruses, although cDNA was found to be present by positive control reactions, PCR products were produced in fewer combinations. The results are given in Table 2, below. Among them, results for PB2 are shown in Fig. 2. These results indicate that the difference in PCR results between the donor virus and the virulent viruses on RT-PCR performance under the same conditions results from the specific binding of primers to a template from the donor virus.

15

TABLE 2

Results of RT-PCR using the primers and templates from the donor virus and the virulent viruses

	PB2	PB1	PA	NP	M	NS	HA	NA
A/Moscow/10/99 (H3N2)					2, 3			
A/Shangdong/9/93 (H3N2)					*			
A/New Caledonia/20/99 (H1N1)	2	1, 2, 4, 5, 7, 8	2, 3, 8, 9	1	1, 2, 3, 7, 8, 9	1, 4, 7		
A/Singapore/6/86 (H1N1)	2, 3, 5, 6, 9	1, 2, 3, 4, 5, 7, 8, 9	1, 2, 3, 7, 8, 9	1, 2, 3, 5, 7, 8, 9	1, 2, 3, 4, 5, 6	1, 3, 4, 5, 6, 7		

EXAMPLE 5: Multiplex RT-PCR detection

Multiplex RT-PCR was carried out using primer sets that were found in Example 4 to produce PCR products from a template from the donor virus while not producing PCR products from templates from the virulent viruses. The
5 selected primer sets were divided into three groups: PB2-2 (1002 bp), NP-4 (853 bp) and PB1-6 (559 bp); PA-5 (730 bp), NS-5 (521 bp) and M-6 (326 bp); and HA-4 (1086 bp) and NA-4 (504 bp), and each group was put into a different tube. In the case of the virulent viruses, multiplex RT-PCR was
10 carried out under the same PCR conditions as in the Monoplex PCR conditions except that primers were used in an amount as high as two to three times that in Monoplex PCR due to the segmented nature of influenza virus genome. As a result, in case of the donor virus, highly reproducible PCR
15 products for all of the eight genes were produced by the amplification in the three tubes. In case of the influenza A/New Caledonia/20/99 (H1N1) and A/Moscow/10/99 (H3N2) viruses, PCR products from the positive control primers for eight genes were produced, but gene amplification did not
20 happen in multiplex PCR tubes (see, Fig. 3). In contrast, multiplex PCR products for all of the eight genes were detected on amplification from the template from the donor virus strain (Fig. 3).

EXAMPLE 6: Genetic analysis of reassortant viruses

25 After reproducible multiplex PCR results from

templates from the donor and virulent viruses were obtained, the multiplex PCR method according to the present invention was practically applied for identification of reassortant viruses.

5 A virulent virus, A/New Caledonia/20/99(H1N1), and the donor virus simultaneously infected a fertilized egg and grown therein. As a result, various reassortant viruses were produced by random combination between RNA segments of the two viruses. From them, viruses containing HA and NA
10 genes from the virulent virus and having the cold adaptation property of the donor virus were selected by culturing at a low temperature and by using an antibody specific to the donor virus. Since virulent viruses also have the growth property at a low temperature, genetic
15 analysis is required to obtain a desired reassortant virus containing the internal genes from the donor virus.

Genetic analysis for the reassortant viruses were preformed according to the same method as in Example 5. The results are given in Table 3, below, and Fig. 4. A
20 reassortant virus No. 7 was expected to be a 6:2 reassortant virus (in which PB2, PB1, PA, NP, M and NS genes are derived from the donor virus, and HA and NA genes are derived from the virulent virus), which produces PCR products for six internal genes while not producing PCR
25 products for two external genes encoding outer envelope proteins. Another reassortant virus No. 2 was expected to be a 5:3 reassortant virus (in which PB2, PB1, NP, M and NS

genes are derived from the donor virus, and PA, HA and NA genes are derived from the virulent virus). The produced reassortant viruses include 4:4 reassortants (containing PA, PB1, NP and M genes from the donor virus and PB2, NS, HA and NA genes from the virulent virus) and a 7:1 reassortant (containing PB2, PB1, PA, NP, M, NS and NA genes from the donor virus and an HA gene from the virulent virus).

In addition, the 6:2 reassortant, reassortant virus No. 7, was subjected to nucleotide sequencing and PCR using nine primer sets for each gene. The results were compared with the results for the donor and virulent viruses (see, Table 4), and, as a result, they were correlated with the results obtained by amplification in four tubes (see, Fig. 4). These results indicate that the origin of eight genes of one recombinant virus can be identified by PCR in three or four tubes, thereby facilitating rapid identification for numerous reassortant viruses.

TABLE 3

Results of analysis according to the present method for viruses produced by reassortment between the virulent virus A/New Caledonia/20/99 (H1N1) and the donor virus HTCA-A101

Reassortant virus No.	No. of segments from donor virus : No. of segments from virulent virus (genes from donor virus)
1	5:3 (PB2, PB1, NP, M, NS)
2	5:3 (PB2, PB1, NP, M, NS)
3	4:4 (PB1, NP, M, NS)
4	4:4 (PB1, NP, PA, M)
5	4:4 (PB1, NP, M, NS)
6	4:4 (PB1, NP, M, NS)
7	6:2 (PB2, PB1, PA, NP, M, NS)
8	5:3 (PB2, PB1, NP, PA, NS)
9	7:1 (PB2, PB1, PA, NP, M, NS, NA)

TABLE 4

Comparison of nucleotide sequences obtained by partial sequencing of PCR products of the reassortant virus 7 with the known sequence of the donor virus HTCA-A101

PCR products	Positions of the partial sequences	Size of the partial sequences	Homology (%)
PB2 (1622-2270) 649 bp	1622-2270	649 bp	100
PB1 (1243-2268) 1026 bp	1345-1906 2002-253	754 bp (562 + 192)	100
PA (34-507) 474 bp	66-501	436 bp	100
NP (392-1505) 1114 bp	60-469	410 bp	99
M (248-914) 649 bp	444-849	406 bp	100
NS (1-612) 612 bp	25-578	554 bp	99
HA (1-600) 600 bp	-	-	No significant homology
NA (1-600) 600 bp	-	-	No significant homology

5 Industrial Applicability

As described hereinbefore, the screening method of reassortant influenza viruses, which is based on performing multiplex RT-PCR using donor virus-specific primer sets designed according to the present invention, allows

selecting viruses having a desired combination from viruses formed by various combinations with small manpower for a short period of time at an intermediate stage of a preparation process of desired reassortant viruses. In addition, the screening method allows preparing desired reassortant viruses in a short time using a circulating virulent virus, thereby securing sufficient production and supply of live vaccine viruses.

Claims

1. A screening method of influenza reassortant viruses by PCR, which comprises designing PCR primer sets producing PCR products for only internal genes of an attenuated donor virus on amplification for eight RNA genome segments of influenza viruses.

2. The screening method according to claim 1, wherein the screening method comprises:

designing PCR primer sets producing PCR products from a genome of an attenuated donor virus while not producing PCR products from a genome of a virulent virus on amplification for eight RNA genome segments of influenza viruses;

infecting a fertilized egg with the virulent virus and the attenuated donor virus and allowing random reassortment between the two viruses to produce reassortant viruses;

preparing cDNA by reverse transcription of an RNA genome of each of the reassortant viruses;

performing PCR for the eight RNA genome segments using the reassortant virus cDNA and a primer set for each of the eight RNA genome segments, wherein the primer set allows PCR products to have different lengths; and

selecting 6:2 reassortant virus with which six internal RNA genome segments (PB2, PB1, PA, NP, M and NS)


from the attenuated influenza virus are amplified while two RNA genome segments encoding outer envelope proteins (HA and NA) from the virulent virus are not amplified in a PCR using primer sets specific to the attenuated donor virus.

5 3. The screening method according to claim 1 or 2, wherein the attenuated donor virus is an HTCA-A101 strain (KCTC 0400 BP).


 4. The screening method according to claim 1 or 2, using for screening influenza reassortant viruses a
10 multiplex PCR method in which amplification of the eight genes is performed in three or four tubes while two or three PCRs occur simultaneously in a single tube.

 5. Primer sets specifically binding to an attenuated donor virus, HTCA-A101, which are shown in Table 1.


1/4
Fig. 1




2/4
Fig. 2




A/Moscow/10/99 (H3N2)



A/New Caledonia/20/99 (H1N1)




A/Shangdong/9/93 (H3N2)




A/Singapore/6/86 (H1N1)

3/4
Fig. 3


A. A/New caledonia/20/99



B. A/Moscow/10/99



4/4
Fig. 4



Sequence Listing

<110> CJ Corporation
Protheon

<120> Screening method of reassortant influenza viruses using primer
dependent multiplex RT-PCR

<150> KR10-2003-0053534

<151> 2003-08-01

<160> 145

<170> KopatentIn 1.71

<210> 1

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PB2-1 sense primer designed from HTCA-A101

<400> 1

aatgacaaat acagttcag

19

<210> 2

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> PB2-1 antisense primer designed from HTCA-A101

<400> 2

gaagaagttt tattatctgt gc

22

<210> 3

<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> PB2-2 sense primer designed from HTCA-A101

<400> 3
cacacagatt ggtggaatt* 19

<210> 4
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> PB2-2 antisense primer designed from HTCA-A101

<400> 4
gaagaagttt tattatctgt gc 22

<210> 5
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> PB2-3 sense primer designed from HTCA-A101

<400> 5
cgacatgact ccaagcatc 19

<210> 6
<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> PB2-3 antisense primer designed from HTCA-A101

<400> 6

gaagaagttt tattatctgt gc

22

<210> 7

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PB2-4 sense primer designed from HTCA-A101

<400> 7

aatgacaaat acagttcag

19

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PB2-4 antisense primer designed from HTCA-A101

<400> 8

gaatgaggaa tcccctcaga

20

<210> 9

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PB2-5 sense primer designed from HTCA-A101

<400> 9

cacacagatt ggtggaatt

19

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PB2-5 antisense primer designed from HTCA-A101

<400> 10

gaatgaggaa tcccctcaga

20

<210> 11

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PB2-6 sense primer designed from HTCA-A101

<400> 11

cgacatgact ccaagcatc

19

<210> 12

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PB2-6 antisense primer designed from HTCA-A101

<400> 12

gaatgaggaa tcccctcaga

20

<210> 13

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PB2-7 sense primer designed from HTCA-A101

<400> 13

aatgacaaat acagttcag

19

<210> 14

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PB2-7 antisense primer designed from HTCA-A101

<400> 14

ctcttgcttt ctttgcccag

20

<210> 15

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PB2-8 sense primer designed from HTCA-A101

<400> 15

cacacagatt ggtggaatt

19

<210> 16

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PB2-8 antisense primer designed from HTCA-A101

<400> 16

ctcttgttctt ctttgcccag

20

<210> 17

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PB2-9 sense primer designed from HTCA-A101

<400> 17

cgacatgact cgaagcatc

19

<210> 18

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PB2-9 antisense primer designed from HTCA-A101

<400> 18

ctcttggtctt cttgcccag

20

<210> 19

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Positive PB2 sense primer designed from HTCA-A101

<400> 19

catcgtcaat gatgtgggag

<210> 20

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Positive PB2 antisense primer designed from HTCA-A101

<400> 20

tggctgtcag taagtatgct

20

<210> 21

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> PB1-1 sense primer designed from HTCA-A101

<400> 21
aaatgttcta agtattgctc ca

22

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PB1-1 antisense primer designed from HTCA-A101

<400> 22
aggttcgata aaacctgtcg

20

<210> 23
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> PB1-2 sense primer designed from HTCA-A101

<400> 23
gagagcaaga gtatgaaact ta

22

<210> 24
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PB1-2 antisense primer designed from HTCA-A101

<400> 24

aggttcgata aaacctgtcg

20

<210> 25

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> PB1-3 sense primer designed from HTCA-A101

<400> 25

ctagcaagca tcgatttgaa a

21

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PB1-3 antisense primer designed from HTCA-A101

<400> 26

aggttcgata aaacctgtcg

20

<210> 27

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> PB1-4 sense primer designed from HTCA-A101

<400> 27

aaatgttcta agtattgctc ca

22

<210> 28

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PB1-4 antisense primer designed from HTCA-A101

<400> 28

gtcacctcta tggcatcgg

19

<210> 29

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> PB1-5 sense primer designed from HTCA-A101

<400> 29

gagagcaaga gtatgaaact ta

22

<210> 30

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PB1-5 antisense primer designed from HTCA-A101

<400> 30

gtcacctcta tggcatcgg

19

<210> 31

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> PB1-6 sense primer designed from HTCA-A101

<400> 31

ctagcaagca tcgatttgaa a

21

<210> 32

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PB1-6 antisense primer designed from HTCA-A101

<400> 32

gtcacctcta tggcatcgg

19

<210> 33

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> PB1-7 sense primer designed from HTCA-A101

<400> 33

aaatgttcta agtattgctc ca

22

<210> 34
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

<223> PB1-7 antisense primer designed from HTCA-A101

<400> 34
catcatcact gcattgttca tt

22

<210> 35
<211> 22
<212> DNA

<213> Artificial Sequence

<220>

<223> PB1-8 sense primer designed from HTCA-A101

<400> 35
gagagcaaga gtatgaaact ta

22

<210> 36
<211> 22
<212> DNA
<213> Artificial Sequence

<220>

<223> PB1-8 antisense primer designed from HTCA-A101

<400> 36
catcatcact gcattgttca tt

22

<210> 37
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> PB1-9 sense primer designed from HTCA-A101

<400> 37
ctagcaagca tcgatttgaa a 21

<210> 38
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> PB1-9 antisense primer designed from HTCA-A101

<400> 38
catcatcact gcattgttca tt 22

<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Positive PB1 sense primer designed from HTCA-A101

<400> 39
atgatgatgg gcattgttcaa 20

<210> 40
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Positive PBI antisense primer designed from HTCA-A101

<400> 40
ggaacagatc ttcatgatct 20

<210> 41
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PA-1 sense primer designed from HTCA-A101

<400> 41
taatcgaggg aagagatcgc 20

<210> 42
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PA-1 antisense primer designed from HTCA-A101

<400> 42
tgtgttcaat tggagccaca 20

<210> 43

<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> PA-2 sense primer designed from HTCA-A101

<400> 43

acaacaccac gaccacttag

20

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> PA-2 antisense primer designed from HTCA-A101

<400> 44

tgtgttcaat tggagccaca

20

<210> 45
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> PA-3 sense primer designed from HTCA-A101

<400> 45

gatggaagga acccaatgtt

20

<210> 46
<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PA-3 antisense primer designed from HTCA-A101

<400> 46

tgtgttcaat tggagccaca

20

<210> 47

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PA-4 sense primer designed from HTCA-A101

<400> 47

taatcgaggg aagagatcgc

20

<210> 48

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> PA-4 antisense primer designed from HTCA-A101

<400> 48

tttatgatga aaccaacaag c

21

<210> 49

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PA-5 sense primer designed from HTCA-A101

<400> 49

acaacaccac gaccacttag

20

<210> 50

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> PA-5 antisense primer designed from HTCA-A101

<400> 50

tttatgatga aaccaacaag c

21

<210> 51

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PA-6 sense primer designed from HTCA-A101

<400> 51

gatggaagga acccaatgtt

20

<210> 52

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> PA-6 antisense primer designed from HTCA-A101

<400> 52

tttatgatga aaccaacaag c

21

<210> 53

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PA-7 sense primer designed from HTCA-A101

<400> 53

taatcgaggg aagagatcgc

20

<210> 54

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PA-7 antisense primer designed from HTCA-A101

<400> 54

gaacatgggc cttgaaacct

20

<210> 55

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PA-8 sense primer designed from HTCA-A101

<400> 55

acaacaccac gaccacttag

20

<210> 56

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PA-8 antisense primer designed from HTCA-A101

<400> 56

gaacatgggc cttgaaacct

20

<210> 57

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PA-9 sense primer designed from HTCA-A101

<400> 57

gatggaagga acccaatggt

20

<210> 58

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PA-9 antisense primer designed from HTCA-A101

<400> 58

gaacatgggc cttgaaacct

20

<210> 59

<211> 19

<212> DNA *

<213> Artificial Sequence

<220>

<223> Positive PA sense primer designed from HTCA-A101

<400> 59

gtagtctgcc tttgtggcc

19

<210> 60

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Positive PA antisense primer designed from HTCA-A101

<400> 60

tcttgtctta tggatgaatag

20

<210> 61

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> NP-1 sense primer designed from HTCA-A101

<400> 61
acctatatac aggagagtaa ac

22

<210> 62
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> NP-1 antisense primer designed from HTCA-A101

<400> 62
aaagcttccc tcttgggagc

20

<210> 63
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> NP-2 sense primer designed from HTCA-A101

<400> 63
gaacaatggt gatggaattg g

21

<210> 64
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> NP-2 antisense primer designed from HTCA-A101

<400> 64

aaagcttccc tcttgggagc

20

<210> 65

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> NP-3 sense primer designed from HTCA-A101

<400> 65

gtgggtacga ctttgaaagg

20

<210> 66

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> NP-3 antisense primer designed from HTCA-A101

<400> 66

aaagcttccc tcttgggagc

20

<210> 67

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> NP-4 sense primer designed from HTCA-A101

<400> 67

acctatatac aggagagtaa ac

22

<210> 68

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> NP-4 antisense primer designed from HTCA-A101

<400> 68

agtgtacttg attccatagt c

21

<210> 69

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> NP-5 sense primer designed from HTCA-A101

<400> 69

gaacaatggt gatggaattg g

21

<210> 70

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> NP-5 antisense primer designed from HTCA-A101

<400> 70

agtgtacttg attccatagt c

21

<210> 71

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> NP-6 sense primer designed from HTCA-A101

<400> 71

gtgggtacga ctttgaaagg

20

<210> 72

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> NP-6 antisense primer designed from HTCA-A101

<400> 72

agtgtacttg attccatagt c

21

<210> 73

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> NP-7 sense primer designed from HTCA-A101

<400> 73

acctatatac aggagagtaa ac

22

<210> 74
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> NP-7 antisense primer designed from HTCA-A101

<400> 74
tgctgccata atggtggttc 20

<210> 75
<211> 21
<212> DNA

<213> Artificial Sequence

<220>
<223> NP-8 sense primer designed from HTCA-A101

<400> 75
gaacaatggt gatggaattg g 21

<210> 76
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> NP-8 antisense primer designed from HTCA-A101

<400> 76
tgctgccata atggtggttc 20

<210> 77
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> NP-9 sense primer designed from HTCA-A101

<400> 77
gtgggtacga ctttgaaagg 20

<210> 78
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> NP-9 antisense primer designed from HTCA-A101

<400> 78
tgctgccata atggtggttc 20

<210> 79
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Positive NP sense primer designed from HTCA-A101

<400> 79
taaggcgaat ctggcgccaa 20

<210> 80
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Positive NP antisense primer designed from HTCA-A101

<400> 80
taagatcctt cattactcat 20

<210> 81
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> M-1 sense primer designed from HTCA-A101

<400> 81
acgtactctc tatcatcccg 20

<210> 82
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> M-1 antisense primer designed from HTCA-A101

<400> 82
tctagcctga ctagcaacc 19

<210> 83

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> M-2 sense primer designed from HTCA-A101

<400> 83
ccatggggcc aaagaaatct 20

<210> 84
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> M-2 antisense primer designed from HTCA-A101

<400> 84
tctagcctga ctagcaacc 19

<210> 85
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> M-3 sense primer designed from HTCA-A101

<400> 85
tctagcctga ctagcaacc 19

<210> 86
<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> M-3 antisense primer designed from HTCA-A101

<400> 86

acgtactctc'tatcatcccg

20

<210> 87

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> M-4 sense primer designed from HTCA-A101

<400> 87

tgatatttgc ggcaatagtg

20

<210> 88

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> M-4 antisense primer designed from HTCA-A101

<400> 88

ccatggggcc aaagaaatct

20

<210> 89

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> M-5 sense primer designed from HTCA-A101

<400> 89

tgatatttgc ggcaatagtg

20

<210> 90

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> M-5 antisense primer designed from HTCA-A101

<400> 90

tgatatttgc ggcaatagtg

20

<210> 91

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> M-6 sense primer designed from HTCA-A101

<400> 91

attgctgact cccagcatc

19

<210> 92

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> M-6 antisense primer designed from HTCA-A101

<400> 92

tgatatttgc ggcaatagtg

20

<210> 93

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> M-7 sense primer designed from HTCA-A101

<400> 93

acgtactctc tatcatcccg

20

<210> 94

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> M-7 antisense primer designed from HTCA-A101

<400> 94

cttccctcat agactttggc

20

<210> 95

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> M-8 sense primer designed from HTCA-A101

<400> 95

ccatggggcc aaagaaatct

20

<210> 96

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> M-8 antisense primer designed from HTCA-A101

<400> 96

cttccctcat agactttggc

20

<210> 97

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> M-9 sense primer designed from HTCA-A101

<400> 97

attgctgact cccagcatc

19

<210> 98

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> M-9 antisense primer designed from HTCA-A101

<400> 98

cttccctcat agactttggc

20

<210> 99

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Positive M sense primer designed from HTCA-A101

<400> 99

gcagcgtaga cgctttgtc

19

<210> 100

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Positive M antisense primer designed from HTCA-A101

<400> 100

ccttcgtag aaggccctc

19

<210> 101

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> NS-1 sense primer designed from HTCA-A101

<400> 101
agttgcagac caagaactag 20

<210> 102
<211> 20
<212> DNA
<213> Artificial Sequence *

<220>
<223> NS-1 antisense primer designed from HTCA-A101

<400> 102
gcaatattag agtctccagc 20

<210> 103
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> NS-2 sense primer designed from HTCA-A101

<400> 103
atcaagacag ccacacgtgc 20

<210> 104
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> NS-2 antisense primer designed from HTCA-A101

<400> 104

gcaatattag agtctccagc

20

<210> 105

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> NS-3 sense primer designed from HTCA-A101

<400> 105

ggaaagcaga tagtgagcg

20

<210> 106

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> NS-3 antisense primer designed from HTCA-A101

<400> 106

gcaatattag agtctccagc

20

<210> 107

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> NS-4 sense primer designed from HTCA-A101

<400> 107

agttgcagac caagaactag

20

<210> 108

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> NS-4 antisense primer designed from HTCA-A101

<400> 108

ctaattgttc ccgccatttc t

21

<210> 109

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> NS-5 sense primer designed from HTCA-A101

<400> 109

atcaagacag ccacacgtgc

20

<210> 110

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> NS-5 antisense primer designed from HTCA-A101

<400> 110

ctaattgttc ccgccatttc t

21

<210> 111

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> NS-6 sense primer designed from HTCA-A101

<400> 111

ggaaagcaga tagtggagcg

20

<210> 112

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> NS-6 antisense primer designed from HTCA-A101

<400> 112

ctaattgttc ccgccatttc t

21

<210> 113

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> NS-7 sense primer designed from HTCA-A101

<400> 113

agttgcagac caagaactag

20

<210> 114
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> NS-7 antisense primer designed from HTCA-A101

*

<400> 114
attctctgtt atcttcagtt

20

<210> 115
<211> 20
<212> DNA

<213> Artificial Sequence

<220>

<223> NS-8 sense primer designed from HTCA-A101

<400> 115
atcaagacag ccacacgtgc

20

<210> 116
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> NS-8 antisense primer designed from HTCA-A101

<400> 116
attctctgtt atcttcagtt

20

<210> 117
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> NS-9 sense primer designed from HTCA-A101

<400> 117
ggaaagcaga tagtggagcg 20

<210> 118
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> NS-9 antisense primer designed from HTCA-A101

<400> 118
attctctggt atcttcagtt 20

<210> 119
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Positive NS sense primer designed from HTCA-A101

<400> 119
agcaaaagca gggtgacaaa 20

<210> 120

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Positive NS antisense primer designed from HTCA-A101

<400> 120

cagagactcg aactgtgtta

20

<210> 121

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> HA-1 sense primer designed from HTCA-A101

<400> 121

ggtttcactt ggactggggt

20

<210> 122

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> HA-1 antisense primer designed from HTCA-A101

<400> 122

tgagaattcc ttttcgattt ga

22

<210> 123

<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> HA-2 sense primer designed from HTCA-A101

<400> 123
tgaccaaatc aggaagca 18

<210> 124
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> HA-2 antisense primer designed from HTCA-A101

<400> 124
tgagaattcc ttttcgattt ga 22

<210> 125
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> HA-3 sense primer designed from HTCA-A101

<400> 125
ggtttcactt ggactggggt 20

<210> 126
<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> HA-3 antisense primer designed from HTCA-A101

<400> 126

gcatccagtc tttgtatcca

20

<210> 127

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> HA-4 sense primer designed from HTCA-A101

<400> 127

tgaccaaadc aggaagca

18

<210> 128

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> HA-4 antisense primer designed from HTCA-A101

<400> 128

gcatccagtc tttgtatcca

20

<210> 129

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Positive H1 control sense primer designed from HTCA-A101

<400> 129

atgaaagcaa aactactagt tca

23

<210> 130

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Positive H1 control antisense primer designed from HTCA-A101

<400> 130

agacgggtga tgaacacccc at

22

<210> 131

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Positive H2 control sense primer designed from HTCA-A101

<400> 131

cctcaacagg tagaatatgc gg

22

<210> 132

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Positive H2 control antisense primer designed from HTCA-A101

<400> 132

aggagcaatt agattccctg tg

22

<210> 133

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> NA-1 sense primer designed from HTCA-A101

<400> 133

agatatgccc caaattagtg

20

<210> 134

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> NA-1 antisense primer designed from HTCA-A101

<400> 134

cgattgttag ccagcccatg cca

23

<210> 135

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> NA-2 sense primer designed from HTCA-A101

<400> 135

tgcgtttgta tcaatgggac

20

<210> 136

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> NA-2 antisense primer designed from HTCA-A101

<400> 136

cgattgttag ccagcccatg cca

23

<210> 137

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> NA-3 sense primer designed from HTCA-A101

<400> 137

agatatgcc ccaattagt

20

<210> 138

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> NA-3 antisense primer designed from HTCA-A101

<400> 138

ctgcgatttg gaattaggtg

20

<210> 139

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> NA-4 sense primer designed from HTCA-A101

<400> 139

tgcgtttgta tcaatgggac

20

<210> 140

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> NA-4 antisense primer designed from HTCA-A101

<400> 140

ctgcgatttg gaattaggtg

20

<210> 141

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Positive N1 control sense primer designed from HTCA-A101

<400> 141

agcaaaagca ggagtttaa a

21

<210> 142

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Positive N1 control antisense primer designed from HTCA-A101

<400> 142

cgattgttag ccagcccatg cca

23

<210> 143

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Positive N2 control sense primer designed from HTCA-A101

<400> 143

atgaatccaa atcaaaagat aa

22

<210> 144

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Positive N2 control antisense primer designed from HTCA-A101

<400> 144

ttgccaggat cgcattgacac at

22

<210> 145

<211> 11

<212> DNA

<213> Artificial Sequence

<220>

<223> Uni12 primer designed from HTCA-A101

<400> 145

agcaaagcag g

11

A. CLASSIFICATION OF SUBJECT MATTER

IPC7 C12Q 1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7 : C12Q 1/68, A61K 39/145

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Korean Patents and application for inventions since 1975

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
MEDLINE, BIOSIS, NPS, PAJ, DELPHION, WPINDEX

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	J. of Clinical Microbiology, vol. 36, no. 10, pp. 2990-2995 (1998) see entire document	1, 2, 4
Y	J. of Clinical Microbiology, vol. 38, no. 2, pp. 839-845 (2000) see entire document	1, 2, 4
A	Analytical Biochemistry vol. 252, no. 1, pp. 24-32 (1997) see entire document	1-5
A	J. of Clinical Microbiology, vol. 39, no. 11, pp. 4097-4102 (2001) see entire document	1-5
A	Virus Research, vol. 32, no. 3, pp. 391-399 (1994) see entire document	1-5

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 DECEMBER 2004 (15.12.2004)

Date of mailing of the international search report

15 DECEMBER 2004 (15.12.2004)

Name and mailing address of the ISA/KR



Korean Intellectual Property Office
920 Dunsan-dong, Seo-gu, Daejeon 302-701,
Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

BAIK, Kyong UP

Telephone No. 82-42-481-5596



INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR2004/001903

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of Item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:

a. type of material

- ☒ a sequence listing
☐ table(s) related to the sequence listing

b. format of material

- ☒ in written format
☒ in computer readable form

c. time of filing/furnishing

- ☒ contained in the international application as filed
☒ filed together with the international application in computer readable form
☐ furnished subsequently to this Authority for the purposes of search

2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments: